Compare OPBK & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPBK | KPTI |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.7M | 172.6M |
| IPO Year | 2018 | 2013 |
| Metric | OPBK | KPTI |
|---|---|---|
| Price | $13.23 | $5.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $16.50 | ★ $17.50 |
| AVG Volume (30 Days) | 31.9K | ★ 659.3K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | ★ 23.74 | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | $3,204,000.00 | ★ $146,067,000.00 |
| Revenue This Year | $16.07 | N/A |
| Revenue Next Year | $11.60 | $46.62 |
| P/E Ratio | $7.25 | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $10.43 | $3.51 |
| 52 Week High | $15.27 | $10.99 |
| Indicator | OPBK | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 26.90 |
| Support Level | $12.74 | $3.95 |
| Resistance Level | $13.24 | $6.96 |
| Average True Range (ATR) | 0.40 | 0.88 |
| MACD | 0.02 | -0.36 |
| Stochastic Oscillator | 55.09 | 5.83 |
OP Bancorp operates its commercial community banking activities through Open Bank its wholly owned banking subsidiary. It provides commercial banking services to small and medium-sized businesses, their owners, and retail customers, with a focus on the Korean-American community. The bank currently operate twelve full service branches: nine branches across Los Angeles and Orange Counties in California, as well as one branch each in Santa Clara, California; Carrollton, Texas; and Las Vegas, Nevada. Additionally, it maintains five loan production offices located in Pleasanton, California; Atlanta, Georgia; Aurora, Colorado; Lynnwood, Washington; and Fairfax, Virginia. Substantially all its business activities are conducted through the Bank.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).